Evidence map›Paper›PMID 31828158›Full record

ArticleJournal of diabetes research2019

Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy.

Saeko Asano, Tatsuhito Himeno, Tomohide Hayami, Mikio Motegi, Rieko Inoue, Hiromi Nakai-Shimoda, Emiri Miura-Yura, Yoshiaki Morishita, Masaki Kondo, Shin Tsunekawa and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Saeko AsanoDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Tatsuhito HimenoDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.ORCID https://orcid.org/0000-0001-8561-7605
Tomohide HayamiDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Mikio MotegiDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Rieko InoueDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Hiromi Nakai-ShimodaDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Emiri Miura-YuraDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Yoshiaki MorishitaDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Masaki KondoDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Shin TsunekawaDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Yoshiro KatoDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Koichi KatoDepartment of Medicine, Aichi Gakuin University School of Pharmacy, Nagoya, Japan.
Keiko NaruseDepartment of Internal Medicine, Aichi Gakuin University School of Dentistry, Nagoya, Japan.ORCID https://orcid.org/0000-0002-0062-0694
Jiro NakamuraDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Hideki KamiyaDivision of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.ORCID https://orcid.org/0000-0003-3197-2542
Aichi Medical University · JPAichi Gakuin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Distal sensory-motor polyneuropathy is one of the most frequent diabetic complications. However, few therapies address the etiology of neurodegeneration in the peripheral nervous systems of diabetic patients. Several metabolic mechanisms have been proposed as etiologies of this polyneuropathy. In this study, we revisited one of those mechanisms, the polyol pathway, and investigated the curative effects of a novel strong aldose reductase inhibitor, ranirestat, in streptozotocin-induced diabetic rats with preexisting polyneuropathy. Twelve weeks after the onset of diabetes, rats which had an established polyneuropathy were treated once daily with a placebo, ranirestat, or epalrestat, over 6 weeks. Before and after the treatment, nerve conduction velocities and thermal perception threshold of hindlimbs were examined. After the treatment, intraepidermal fiber density was evaluated. As an ex vivo assay, murine dorsal root ganglion cells were dispersed and cultured with or without 1

Indexed as

Aldehyde ReductaseAnimalsDiabetes Mellitus, ExperimentalDiabetic NeuropathiesEnzyme InhibitorsEpidermisGanglia, SpinalIn Vitro TechniquesMiceNerve FibersNeural ConductionNeuronal OutgrowthPyrazinesRatsRats, WistarSensory Receptor CellsAldehyde ReductaseEnzyme InhibitorsPyrazinesranirestatSpiro Compounds

Identifiers

PMID31828158
PMCPMC6885776
OpenAlexW2986680536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.